

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Orbifloxacin / Posaconazole / Mometasone Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 50 Tuas West Drive  
Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS Classification**

Serious eye damage/eye irritation : Category 2B

Long-term (chronic) aquatic hazard : Category 2

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H320 Causes eye irritation.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.

**Response:**

# Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
 Date of first issue: 06.01.2016

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337 + P313 If eye irritation persists: Get medical advice/ attention.

P391 Collect spillage.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

None known.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name                 | CAS-No.     | Concentration (% w/w) |
|-------------------------------|-------------|-----------------------|
| White mineral oil (petroleum) | 8042-47-5   | >= 50 -< 70           |
| Orbifloxacin                  | 113617-63-3 | >= 1 -< 3             |
| Posaconazole                  | 171228-49-2 | >= 0.1 -< 0.25        |
| Mometasone                    | 83919-23-7  | >= 0.1 -< 0.25        |

## 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes eye irritation.

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

# Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe vapours or spray mist.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

| Components                    | CAS-No.     | Value type (Form of exposure)      | Control parameters / Permissible concentration | Basis    |
|-------------------------------|-------------|------------------------------------|--|----------|
| White mineral oil (petroleum) | 8042-47-5   | PEL (long term) (Mist)             | 5 mg/m <sup>3</sup>                            | SG OEL   |
|                               |             | PEL (short term) (Mist)            | 10 mg/m <sup>3</sup>                           | SG OEL   |
|                               |             | TWA (Inhalable particulate matter) | 5 mg/m <sup>3</sup>                            | ACGIH    |
| Orbifloxacin                  | 113617-63-3 | TWA                                | 0.2 mg/m <sup>3</sup> (OEB 2)                  | Internal |
| Posaconazole                  | 171228-49-2 | TWA                                | 300 µg/m <sup>3</sup> (OEB 2)                  | Internal |
| Mometasone                    | 83919-23-7  | TWA                                | 1 µg/m <sup>3</sup> (OEB 4)                    | Internal |
| Further information: Skin     |             |                                    |  |          |
|                               |             | Wipe limit                         | 10 µg/100 cm <sup>2</sup>                      | Internal |

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type  
Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.  
Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension  
Colour : white to off-white  
Odour : odourless

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

---

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : Can react with strong oxidizing agents.  
Conditions to avoid : None known.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported  
No mortality observed at this dose.

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported

**Components:****White mineral oil (petroleum):**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**Orbifloxacin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg  
Remarks: No mortality observed at this dose.

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

LD50 (Dog): > 600 mg/kg  
Symptoms: Vomiting  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg  
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg  
Application Route: Intravenous

### Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

### Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

### Skin corrosion/irritation

Not classified based on available information.



**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**Product:**

Species : Rabbit  
Result : Mild skin irritation

**Components:****White mineral oil (petroleum):**

Species : Rabbit  
Result : No skin irritation

**Orbifloxacin:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Posaconazole:**

Species : Rabbit  
Result : No skin irritation

**Mometasone:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes eye irritation.

**Product:**

Species : Rabbit  
Result : Mild eye irritation

**Components:****White mineral oil (petroleum):**

Species : Rabbit  
Result : No eye irritation

**Orbifloxacin:**

Species : Rabbit  
Result : Mild eye irritation  
Method : Draize Test

**Posaconazole:**

Species : Rabbit  
Result : Mild eye irritation

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**Mometasone:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Product:**

Test Type : Magnusson-Kligman-Test  
Exposure routes : Dermal  
Result : Not a skin sensitizer.

**Components:****White mineral oil (petroleum):**

Test Type : Buehler Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

**Orbifloxacin:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

**Posaconazole:**

Test Type : Magnusson-Kligman-Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

**Mometasone:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Assessment : Does not cause skin sensitisation.  
Result : negative  
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: Based on data from similar materials

**Orbifloxacin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: equivocal

Test Type: Mouse Lymphoma  
Result: positive

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Application Route: Oral  
Result: negative

Germ cell mutagenicity -  
Assessment : Weight of evidence does not support classification as a germ  
cell mutagen.

**Posaconazole:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intravenous  
Result: negative

**Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

|                   |   |           |
|-------------------|---|-----------|
| Species           | : | Rat       |
| Application Route | : | Ingestion |
| Exposure time     | : | 24 Months |
| Result            | : | negative  |

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**Orbifloxacin:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

**Posaconazole:**

Species : Rat  
Application Route : oral (feed)  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

**Mometasone:**

Species : Rat  
Application Route : Inhalation  
Exposure time : 2 Years  
Dose : 0.067 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Inhalation  
Exposure time : 19 Months  
Dose : 0.160 mg/kg body weight  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Skin contact  
Result: negative

## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
 Date of first issue: 06.01.2016

---

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Oral  
 General Toxicity - Parent: NOAEL: 50 mg/kg body weight  
 Early Embryonic Development: NOAEL: 50 mg/kg body weight  
 Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Oral  
 Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight  
 Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 General Toxicity Maternal: NOAEL: 20 mg/kg body weight  
 Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight  
 Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development  
 Species: Dog  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 2.5 mg/kg body weight  
 Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male  
 General Toxicity - Parent: NOAEL: 180 mg/kg body weight  
 Symptoms: No effects on mating performance  
 Result: negative

## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
 Date of first issue: 06.01.2016

---

Test Type: Fertility/early embryonic development  
 Species: Rat, female  
 General Toxicity - Parent: NOAEL: 45 mg/kg body weight  
 Symptoms: No effects on mating performance  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat, female  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 29 mg/kg body weight  
 Result: Fetotoxicity, Malformations were observed.

Test Type: Embryo-foetal development  
 Species: Rabbit, female  
 Developmental Toxicity: LOAEL: 40 mg/kg body weight  
 Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### **Mometasone:**

Effects on fertility : Test Type: Fertility  
 Species: Rat  
 Application Route: Subcutaneous  
 Fertility: NOAEL: 0.015 mg/kg body weight  
 Symptoms: Reduced embryonic survival, Reduced foetal weight  
 Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Mouse  
 Application Route: Subcutaneous  
 Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight  
 Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Dermal  
 Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
 Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Dermal  
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
 Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

Species: Rat  
 Application Route: Subcutaneous  
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
 Result: Effects on newborn

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
 Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

#### Components:

##### **Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### **Posaconazole:**

Exposure routes : Ingestion  
 Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

##### **Mometasone:**

Exposure routes : inhalation (dust/mist/fume)  
 Target Organs : Immune system, Liver, Kidney, Skin  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **White mineral oil (petroleum):**

Species : Rat  
 LOAEL : 160 mg/kg  
 Application Route : Ingestion



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
 Date of first issue: 06.01.2016

---

Exposure time : 90 Days  
 Species : Rat  
 LOAEL :  $\geq 1$  mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 4 Weeks  
 Method : OECD Test Guideline 412

### Orbifloxacin:

Species : Rat  
 NOAEL : 20 mg/kg  
 LOAEL : 80 mg/kg  
 Application Route : Oral  
 Exposure time : 3 Months  
 Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse  
 NOAEL : 80 mg/kg  
 LOAEL : 250 mg/kg  
 Application Route : Oral  
 Exposure time : 3 Months

Species : Juvenile dog  
 NOAEL : 50 mg/kg  
 LOAEL : 250 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Days  
 Target Organs : Heart, Bone  
 Symptoms : Gastrointestinal disturbance  
 Remarks : mortality observed

Species : Juvenile dog  
 NOAEL : 2 mg/kg  
 LOAEL : 3 mg/kg  
 Application Route : Oral  
 Exposure time : 90 Days  
 Target Organs : Bone  
 Remarks : No significant adverse effects were reported

Species : Dog  
 NOAEL : 37.5 mg/kg  
 Application Route : Oral  
 Exposure time : 30 Days

Species : Cat  
 NOAEL : 7.5 mg/kg  
 LOAEL : 22.5 mg/kg  
 Application Route : Oral  
 Exposure time : 1 Months  
 Symptoms : Gastrointestinal disturbance

**Orbifloxacin / Posaconazole / Mometasone  
Formulation**

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

**Posaconazole:**

Species : Rat, female  
LOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 392 Days  
Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species : Monkey  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 56 Weeks  
Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species : Monkey  
LOAEL : 180 mg/kg  
Application Route : Oral  
Exposure time : 12 Months  
Target Organs : Blood, Gastrointestinal tract, spleen

Species : Monkey  
LOAEL : 8 mg/kg  
Application Route : Intravenous  
Exposure time : 1 Months  
Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

**Mometasone:**

Species : Rat  
NOAEL : 0.005 mg/kg  
LOAEL : 0.3 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog

## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.15      Revision Date: 30.09.2023      SDS Number: 439124-00018      Date of last issue: 04.04.2023  
 Date of first issue: 06.01.2016

---

LOAEL : 0.5 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d  
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
 NOAEL : 0.00013 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 90 d  
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog  
 NOAEL : 0.0005 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 90 d  
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

### Aspiration toxicity

Not classified based on available information.

### Components:

#### **Mometasone:**

Not applicable

### Experience with human exposure

### Components:

#### **Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
 Remarks: May cause photosensitisation.

#### **Posaconazole:**

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

#### **Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

### Further information

### Components:

#### **Mometasone:**

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

Remarks : Dermal absorption possible

### 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **White mineral oil (petroleum):**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l  
Exposure time: 28 d
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1,000 mg/l  
Exposure time: 21 d

##### **Posaconazole:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 1

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

- icity)  
 Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l  
 Exposure time: 33 d  
 Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.244 mg/l  
 Exposure time: 21 d  
 Method: OECD Test Guideline 211  
 Remarks: No toxicity at the limit of solubility
- M-Factor (Chronic aquatic toxicity) : 1
- Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209
- Mometasone:**
- Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l  
 Exposure time: 96 h  
 Remarks: No toxicity at the limit of solubility
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l  
 Exposure time: 7 d  
 Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility
- EC50 (Americamysis): > 5 mg/l  
 Exposure time: 96 h  
 Method: US-EPA OPPTS 850.1035  
 Remarks: No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l  
 Exposure time: 32 d  
 Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l  
 Exposure time: 21 d  
 Method: OECD Test Guideline 211

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

### Persistence and degradability

#### Components:

##### **White mineral oil (petroleum):**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 31 %  
Exposure time: 28 d

##### **Posaconazole:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 h  
Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d  
Method: OECD Test Guideline 111

##### **Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 % (12 d)  
Method: OECD Test Guideline 111

### Bioaccumulative potential

#### Components:

##### **Posaconazole:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

Bioconcentration factor (BCF): 20  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.15

### Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

### Mobility in soil

### Components:

#### Posaconazole:

Distribution among environmental compartments : log Koc: 5.52

#### Mometasone:

Distribution among environmental compartments : log Koc: 4.02

### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Mometasone, Posaconazole)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

### IATA-DGR

|  |  |
|--|--|
| UN/ID No.                                | : UN 3082  |
| Proper shipping name                     | : Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole) |
| Class                                    | : 9  |
| Packing group                            | : III  |
| Labels                                   | : Miscellaneous  |
| Packing instruction (cargo aircraft)     | : 964  |
| Packing instruction (passenger aircraft) | : 964  |
| Environmentally hazardous                | : yes  |

### IMDG-Code

|                      |  |
|----------------------|--|
| UN number            | : UN 3082  |
| Proper shipping name | : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole) |
| Class                | : 9  |
| Packing group        | : III  |
| Labels               | : 9  |
| EmS Code             | : F-A, S-F   |
| Marine pollutant     | : yes  |

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

#### Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

|  |                  |
|--|------------------|
| Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations | : Not applicable |
|--|------------------|

|   |                  |
|---|------------------|
| Fire Safety (Petroleum and Flammable Materials) Regulations | : Not applicable |
|---|------------------|

The components of this product are reported in the following inventories:



## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

|       |   |                |
|-------|---|----------------|
| AICS  | : | not determined |
| DSL   | : | not determined |
| IECSC | : | not determined |

### 16. OTHER INFORMATION

Revision Date : 30.09.2023

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
 SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term  
 SG OEL / PEL (short term) : Permissible Exposure Level (PEL) Short Term

AICC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation,

# SAFETY DATA SHEET



## Orbifloxacin / Posaconazole / Mometasone Formulation

|         |                |              |                                 |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number:  | Date of last issue: 04.04.2023  |
| 3.15    | 30.09.2023     | 439124-00018 | Date of first issue: 06.01.2016 |

---

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN